Filing Flows

Filing Flows › Companies › Bio Green Med Solution › Cash flow

Bio Green Med Solution cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$352K in Q2 2026 · −$1.1M over twelve months

Operating cash flow−$352K
Free cash flow−$352K

Analysis

In Q2 2026, Bio Green Med Solution generated −$352K of operating cash flow. That is $704K more than in Q2 2025 (−$1.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$1.1M; the largest uses were other financing ($1.2M), operating cash flow ($1.1M); besides operations, cash came from shares issued ($1.8M); the cash balance fell by $485K.

Operating cash flow was −$352K against net income of −$405K. The largest differences: receivables +$114K, payables −$103K, prepaid and other assets +$67K.

Free cash flow

Bio Green Med Solution: free cash flow by quarterBio Green Med Solution: free cash flow by quarter−$3.1MQ3 2024−$1.4MQ4 2024−$3.2MQ1 2025−$1.1MQ2 2025−$434KQ3 2025−$33KQ4 2025−$279KQ1 2026−$352KQ2 2026
Operating cash flow less capital spending.
Bio Green Med Solution: operating cash flow against capital spendingBio Green Med Solution: operating cash flow against capital spendingOperating cash flowCapital spending−$3.1M$0Q3 2024−$1.4M$0Q4 2024−$3.2M$0Q1 2025−$1.1M$0Q2 2025−$434K$0Q3 2025−$33K$0Q4 2025−$278K$1KQ1 2026−$352K$0Q2 2026
Latest (Q2 2026): Operating cash flow −$352K, Capital spending $0.

Capital allocation, year by year

Bio Green Med Solution: where the cash came from (up) and went (down), by fiscal yearBio Green Med Solution: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$18.5MFY2021: Shares issued $4.0MFY2021: Capital spending −$27K$4.0MFY2021FY2022: Operating cash flow −$20.8MFY2022: Capital spending −$7KFY2022FY2023: Operating cash flow −$16.1MFY2023: Shares issued $1.0MFY2023: Capital spending −$6K$1.0MFY2023FY2024: Operating cash flow −$8.0MFY2024: Shares issued $6.2M$6.2MFY2024FY2025: Operating cash flow −$4.8MFY2025: Shares issued $6.4M$6.4MFY2025
Over these 5 years operating cash flow totalled −$68.2M; the largest uses were operating cash flow ($68.2M) and capital spending ($40K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$3.8M
Debtnone
Net cash$3.8M
Cash runway3.5 years

Bio Green Med Solution is burning cash: its operations consume cash, a free cash flow of −$1.1M a year at the current rate against $3.8M of cash and investments: a runway of about 3.5 years before any new financing.

Where the cash came from and went

Bio Green Med Solution: sources (+) and uses (−) of cash, Q2 2026Bio Green Med Solution: sources (+) and uses (−) of cash, Q2 2026Shares issued$794KCash drawn (+) / kept (−)−$451KOperating cash flow−$352KExchange rates$30KOther financing−$21K
Bio Green Med Solution: sources (+) and uses (−) of cash, TTM to Q2 2026Bio Green Med Solution: sources (+) and uses (−) of cash, TTM to Q2 2026Shares issued$1.8MOther financing−$1.2MOperating cash flow−$1.1MCash drawn (+) / kept (−)$485KExchange rates−$3KNot reconciled−$1K

From profit to cash

Bio Green Med Solution: net income to operating cash flow, Q2 2026Bio Green Med Solution: net income to operating cash flow, Q2 2026Net income−$405KReceivables$114KInventory−$25KPayables−$103KPrepaid and other assets$67KOperating cash flow−$352K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$352K—$794K−$451K−$352K
Q1 2026−$278K−$1K$125K$166K−$279K
Q4 2025−$33K—$861K$333K−$33K
Q3 2025−$434K—−$3K$437K−$434K
Q2 2025−$1.1M—$1.7M−$825K−$1.1M
Q1 2025−$3.2M—$3.9M−$313K−$3.2M
Q4 2024−$1.4M——−$155K−$1.4M
Q3 2024−$3.1M—−$1K$3.0M−$3.1M

Bio Green Med Solution: income statement and cash flow

Bio Green Med Solution, Q2 2026: revenue $357K, operating margin -117.1%. The chart follows the revenue to costs, profit and cash.

Bio Green Med Solution: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.